AROPAX

This brand name is authorized in Australia, Brazil, New Zealand, South Africa.

Active ingredients

The drug AROPAX contains one active pharmaceutical ingredient (API):

1	Paroxetine UNII X2ELS050D8 - PAROXETINE HYDROCHLORIDE
	Paroxetine is a potent and selective inhibitor of 5-hydroxytryptamine (5-HT, serotonin) uptake and its antidepressant action and effectiveness in the treatment of OCD, Social Anxiety disorder/Social Phobia, General Anxiety Disorder, Post-Traumatic Stress Disorder and Panic Disorder is thought to be related to its specific inhibition of 5-HT uptake in brain neurones.
	Read more about Paroxetine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
AROPAX CR Tablet	MPI, Generic	Health Products Regulatory Authority (ZA)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N06AB05	Paroxetine	N Nervous system → N06 Psychoanaleptics → N06A Antidepressants → N06AB Selective serotonin reuptake inhibitors
Discover more medicines within N06AB05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	2242B
BR	Câmara de Regulação do Mercado de Medicamentos	510600902111311
NZ	Medicines and Medical Devices Safety Authority	6182
ZA	Health Products Regulatory Authority	A38/1.2/0613, Y/1.2/419